Heterologous viral protein interactions within licensed seasonal influenza virus vaccines

Marina Koroleva(University of Rochester Medicine), Andrea J. Sant(University of Rochester Medical Center), Francisco A. Chaves(University of Rochester Medicine), Savannah A Moritzky(University of Rochester Medicine), Frances Batarse(University of Rochester Medicine), Florian Krammer(Semmelweis University), Carole Henry(Moderna Therapeutics (United States)), Katherine A. Richards(University of Rochester Medicine), Patrick C. Wilson(Cornell University)
npj Vaccines
January 10, 2020
10.1038/s41541-019-0153-1
Cited by 24

Related Papers

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
|Nature|2020|1.7k
Influenza
|Nature Reviews Disease Primers|2018|1.5k
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
|Nature|2021|882
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
|New England Journal of Medicine|2021|803
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
|Immunity|2021|713